The Market Visit has been organised by the Mayor of London's Export Programme, in partnership with UK Trade & Investment (UKTI), to offer London's small-to-medium sized enterprises (SMEs) an opportunity to attend this major industry international event where they will get a chance to mingle with representatives of the world's leading pharmaceutical and biotechnology companies.
Last year's convention featured more than 1,800 exhibitors and 55 state, regional and country pavilions in an area of over 160,000 square feet. The convention was visited by attendees from leading biotech companies, top 25 pharma companies and more than 300 academic institutions, including research labs and government agencies, ValiRx reported.
Furthermore, according to the 2013 Campbell Alliance's “Deal Makers' Intentions” report, the majority of successful deals in the biopharma industry are a result of participating in these sorts of partnering events.
“I look forward to the company building its profile on the international stage, particularly following our successful poster presentation at the recent American Association for Cancer Research (AACR) conference in Philadelphia and I look forward to ValiRx expanding its network of relationships to the benefit of our shareholders," he added.
Shares in ValiRx were up 2.4% in late morning trading.